<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174679</url>
  </required_header>
  <id_info>
    <org_study_id>DOTATATE12-001920EA</org_study_id>
    <nct_id>NCT02174679</nct_id>
  </id_info>
  <brief_title>68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)</brief_title>
  <official_title>68Ga-DOTATATE Imaging in Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine
      tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an expanded access study with a total of 300 participants with NET and suspected SSTR
      positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study
      participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients
      referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then
      accepted for scanning if clinically appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Carcinoid Cancer</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Cancers Expressing Somatostatin Receptors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga DOTATATE</intervention_name>
    <description>Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.</description>
    <other_name>68Ga DOTATATE PET/CT Scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years the time of radiotracer administration

          -  Provides written informed consent

          -  Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age
             must have a negative pregnancy test at screening/baseline

          -  Able to remain still for duration of each imaging procedure (about 30 minutes)

        Exclusion Criteria:

          -  Less than 18 years-old at the time of radiotracer administration

          -  Pregnant or nursing

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Any additional medical condition, serious concurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Czernin, MD</last_name>
    <email>jczernin@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Johannes Czernin, MD</last_name>
      <email>jczernin@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Allen-Auerbach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pawan Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiaan Schiepers, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pet.ucla.edu</url>
    <description>UCLA Ahmanson Translational Imaging Division</description>
  </link>
  <reference>
    <citation>Modlin IM, Kidd M, Hinoue T, Lye KD, Murren J, Argiris A. Molecular strategies and 111in-labelled somatostatin analogues in defining the management of neuroendocrine tumour disease: a new paradigm for surgical management. Surgeon. 2003 Jun;1(3):137-43.</citation>
    <PMID>15570748</PMID>
  </reference>
  <reference>
    <citation>Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006 Aug;40(7):572-82. Review.</citation>
    <PMID>16917396</PMID>
  </reference>
  <reference>
    <citation>Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med. 2011 Dec;52 Suppl 2:56S-63S. doi: 10.2967/jnumed.110.085746. Review.</citation>
    <PMID>22144556</PMID>
  </reference>
  <reference>
    <citation>Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3.</citation>
    <PMID>20596866</PMID>
  </reference>
  <reference>
    <citation>Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Sch√§fer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26. Epub 2007 May 23.</citation>
    <PMID>17520251</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

